A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Inclusion: * Male participants or female participants of nonchildbearing potential between 18 and 75 years of age (inclusive) at the time of Screening. * Body mass index between 18 and 40 kg/m\^2 (inclusive) at the time of Screening. * Eligible participants classified based on established need for renal replacement therapy and eGFR at Screening. Assignment will be based on eGFR at Screening. 1. Group 1 (Normal): eGFR ≥ 90 mL/min and no history of renal disease. 2. Group 2 (Mild): 60 ≤ eGFR ≤ 89 mL/min. 3. Group 3 (Moderate): 30 ≤ eGFR ≤ 59 mL/min. 4. Group 4 (Severe): 15 ≤ eGFR ≤ 29 mL/min without dialysis. 5. Group 5 (Kidney Failure): eGFR \< 15 mL/min and dialysis patients (off-dialysis). 6. Group 6 (Kidney Failure): eGFR \< 15 mL/min and dialysis patients (on-dialysis). Exclusion: * Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of normal. * Clinically significant hyperkalemia (defined by serum potassium concentration as \> 5.5 mEq/L for Groups 1 to 4, \> 6 mEq/L for Groups 5 and 6) at Screening or Check-in. * History of hypersensitivity, intolerance, or allergy to any drug compound, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor. * Female participants with a positive pregnancy test at Screening or Check-in. * Participant has received a dose of an investigational drug within the past 30 days or 5 halflives, whichever is longer, prior to Check-in. Participants in Group 1 only (participants with normal renal function) are excluded if: • A history of renal disease or renal injury as indicated by medical history or an abnormal renal function profile at Screening or Check-in. Participants in Groups 2 to 6 (participants with varying degrees of renal impairment) are excluded if: • A change in disease status within 30 days of Screening, as documented by the participant's medical history, deemed clinically significant by the Investigator.